Epidemiological studies have established human papillomavirus (HPV) infection as the central cause of invasive cervical cancer (ICC) and its precursor lesions ([Walboomers *et al*, 1999](#bib8){ref-type="other"}). However, only a fraction of precancerous lesions progress to ICC. A strong candidate factor for differential progression is HPV type ([Lorincz *et al*, 1992](#bib5){ref-type="other"}).

Identifying HPV types that preferentially progress from high-grade squamous intraepithelial lesions (HSIL) to ICC has implications not only for follow-up protocols in ICC screening programmes, but also for prophylactic type-specific HPV vaccine trials. For ethical reasons, final outcome measures in such trials will be the prevention of HSIL. However, it is important to know whether the HPV type distribution in HSIL is representative of those that go on to cause cancer.

Articles presenting HPV type-specific prevalence data were identified from *Medline*. Studies had to include at least 20 cases of squamous cell or histologically unspecified cervical cancer ([Clifford *et al*, 2002](#bib2){ref-type="other"}) and/or 20 histologically verified cases of HSIL. In this study, HSIL refers both to lesions classified by the Bethesda system, that is, CIN2/3, and those classified separately as CIN2 and CIN3. Studies had to use polymerase chain reaction (PCR)-based assays to identify HPV, and to present prevalence of at least one type other than HPV6, 11, 16 or 18 ([Clifford *et al*, 2002](#bib2){ref-type="other"}).

This report includes 8594 squamous cell carcinoma of the cervix (SCC) cases (including 2725 of unspecified histology), as previously reported in [Clifford *et al* (2002)](#bib2){ref-type="other"}, and 4338 HSIL cases (1733 reported as CIN2/3, 1824 as CIN3, 729 as CIN2 and 52 as cervical carcinoma *in situ*)(detailed information on the HSIL studies is reported in the [Appendix](#app1){ref-type="app"}). Compared to SCC, cases of HSIL were more likely to be from (i) Europe and South/Central America rather than other regions, (ii) studies that detected HPV from exfoliated cells rather than biopsy specimens and (iii) studies that used 'broad'-spectrum (MY09/11, GP5+/6+ and SPF10) rather than other PCR primers ([Table 1](#tbl1){ref-type="table"} Table 1Distribution of SCC and HSIL cases by region and study characteristics**LesionNo. of studiesNo. of casesSource region (% of cases)Cervical specimen for HPV testing (% of cases)PCR primers used (% of cases)**SCC788594Africa (6.9), Asia (31.7), Broad spectrum^a^ (61.9)   Europe (32.0), North America/AustraliaBiopsies (83.4)Narrow spectrum^b^ (15.5)   (13.0), South/Central America (16.5)Exfoliated cells (16.6)Combination/other (16.3)     Type-specific only (6.4)           Broad spectrum^a^ (80.8)HSIL534338Africa (1.8), Asia (16.7), EuropeBiopsies (34.1)Narrow spectrum^b^ (7.9)   (52.4), North America (10.3),Exfoliated cells (65.9)Combination/other (7.4)   South/Central America (18.8) Type-specific only (3.9)[^1][^2][^3]).

Type-specific prevalence is presented for the 14 most common high-risk (HR) types identified in SCC ([Table 2](#tbl2){ref-type="table"} Table 2Comparison of overall and type-specific HPV prevalence between SCC and HSIL cases **SCCHSILSCC : HSILHPV type***n***HPV (%)***n***HPV (%)prevalence ratio^a^**All855087.6433884.21.04(1.03, 1.06)       16859454.3433845.01.21(1.16, 1.26)18850212.643387.11.79(1.56, 2.10)3384494.343027.20.59(0.53, 0.68)4551744.222142.31.85(1.35, 2.91)3172044.240368.80.48(0.43, 0.54)5856463.021756.90.43(0.37, 0.52)5253042.521535.20.48(0.40, 0.60)3562231.026904.40.22(0.18, 0.27)5944880.816361.50.55(0.38, 0.97)5644930.721103.00.23(0.18, 0.31)5145800.621712.90.20(0.16, 0.27)6841480.517631.00.50(0.33, 1.04)3938990.418411.10.35(0.24, 0.66)6647990.217782.10.10(0.08, 0.15)[^4][^5]). As not all studies tested for all 14 types, sample size varies between type-specific analyses. Type-specific prevalence is expressed as a percentage of all cases tested for HPV, and thus represents the prevalence in either single or multiple infections.

Overall, HPV prevalence was slightly higher in SCC cases (87.6%) than HSIL (84.2%) (SCC : HSIL ratio 1.04, 95% CI 1.03--1.06) ([Table 2](#tbl2){ref-type="table"}). HPV16 was the most common type in both SCC (54.3%) and HSIL (45.0%), but was more prevalent in SCC (ratio of 1.21, 95% CI 1.16--1.26). HPV18 was also more prevalent in SCC (12.6%) than in HSIL (7.0%), with a ratio of 1.79 (95% CI 1.56--2.10). HPV45 was associated with a ratio of 1.85 (95% CI 1.35--2.91), similar to that of HPV18. All other HR types included in the analysis had ratios between 0.1 and 0.6 ([Table 2](#tbl2){ref-type="table"}).

The SCC : HSIL ratios for the eight most common HPV types were additionally calculated within more homogeneous study subgroups: (i) studies that did not report any multiple infections (6558 SCC, 2182 HSIL), (ii) studies testing for HPV from biopsies (7128 SCC, 1483 HSIL) and (iii) studies using 'broad'-spectrum PCR primers (5318 SCC, 3502 HSIL). The SCC : HSIL ratios were also calculated separately for HSILs classified by the Bethesda system and for CIN3 only. Across all these subanalyses, SCC : HSIL ratios remained consistent for HPV16 (range: 1.04--1.25), HPV18 (1.46--1.93) and HPV45 (1.20--4.61). HPV31, 33, 35, 52 and 58 were consistently associated with ratios of 0.3--0.9, with the exception of HPV58 for biopsy studies (1.06, 95% CI 0.73--2.08).

Where sample size permitted, subanalyses were also stratified by region. When estimated from studies within Asia, Europe and South/Central America, respectively, there was no material difference in SCC : HSIL ratios for HPV16 (1.46, 1.17, 1.40), HPV18 (1.74, 2.02, 1.46), HPV45 (4.35, 1.39, 1.20), HPV33 (0.56, 0.62, 0.76), HPV52 (0.39, 0.26, 0.64) or HPV58 (0.55, 0.24, 0.30). However, notably high ratios were observed for HPV31 in South/Central America (1.13, 95% CI 0.84--1.70) in comparison to Europe (0.41, 95% CI 0.36--0.48) and Asia (0.43, 95% CI 0.31--0.68), and for HPV58 in China (including Taiwan and Hong Kong) (1.27, 95% CI 0.85--2.51) in comparison to non-Chinese Asian countries (0.37, 95% CI 0.27--0.58), raising the possibility of localised variation in the malignant potential of particular HPV types ([Chan *et al*, 2002](#bib1){ref-type="other"}).

Our findings suggest that worldwide, HSIL infected with HPV16, 18 or 45 are more likely to progress to SCC than HSIL infected with other HR types. This could be interpreted in two ways: either these types have a greater potential to induce fully malignant transformation, and/or these infections somehow preferentially evade the host immune system. Compared to other HPV types, HPV18 has been associated with increased oncogenic potential in cell culture, screening failures and poorer cancer prognosis ([Hildesheim *et al*, 1999](#bib3){ref-type="other"}; [Schwartz *et al*, 2001](#bib7){ref-type="other"}; [Woodman *et al*, 2003](#bib9){ref-type="other"}). Thus, HPV18 enrichment in SCC may reflect its greater oncogenic potential. Given its genetic similarity to HPV18, this may also be true for HPV45. Conversely, compared to other HPV types, HPV16 infections are more likely to persist and progress to HSIL ([Molano *et al*, in press](#bib6){ref-type="other"}). Both persistence of infection and progression to HSIL have been shown associated with HPV16 variants ([Londesborough *et al*, 1996](#bib4){ref-type="other"}). Thus, HPV16 enrichment in SCC may be related to its greater ability to escape immune surveillance compared to other types.

Even in countries with established screening programmes, women still die from rapidly progressing cancers that escape periodic examination. Given that HPV16, 18 and 45 appear to have greater progressive potential, and in the event that future cervical screening programmes include HPV typing, women infected with HPV16, 18 and 45 may require closer surveillance than women infected with other HR HPV types.

The demonstration that the HPV type distribution in HSIL is not entirely representative of those that go on to cause cancer also has important implications for prophylactic type-specific HPV vaccine evaluation. This is because any beneficial effect identified by randomised trials from the proportion of HSIL preventable by HPV16 or HPV16/18 vaccines may be an underestimate of the beneficial effect on the prevention of ICC.

The work reported in this paper was undertaken by Dr Gary Clifford during the tenure of an IARC Postdoctoral Fellowship from the International Agency for Research on Cancer. We thank Dr Massimo Tommasino for his critical comments during the preparation of the manuscript.

Study methods and type-specific prevalence of human papillomavirus by study and by region are summarised in [Table A1](#tbla1){ref-type="table"} Table A1        **HPV-specific prevalence (% of all cases tested)First authorReferenceCountryHPV DNA sourcePCR primers used to identify all HPV +veNo. casesCINII/CINIII/CIS/HSILAny1618453133585235595651683966***Africa*                      La Ruche*Int J Cancer* (1998)Ivory CoastExfol. cellsMY09/11490/0/0/4977.630.610.20.06.18.28.24.10.00.04.10.02.00.0  de Vuyst*Sex Transm Dis* (2003)KenyaExfol. cellsSPF10290/0/0/2996.634.53.46.96.93.46.924.117.20.03.410.36.90.010.3                      *Africa sub-total*    780/0/0/7884.632.17.72.66.46.47.711.56.40.03.83.83.80.010.3                      *Asia*                      Chan MKM*Gynecol Oncol* (1996)ChinaExfol. cellsMY09/114510/35/0/055.624.48.9 0.04.4          Chan PKS*J Med Virol* (1999)ChinaExfol. cellsMY09/118929/60/0/058.425.84.50.03.46.711.21.10.00.00.00.00.01.10.0 Wu CH*Sex Transm Dis* (1994)ChinaFixed biopsiesTS-PCR only3413/15/6/076.535.320.6 0.05.9          Nagai Y*Gynecol Oncol* (2000)JapanExfol. cellsL1C1/L1C2580/58/0/096.637.93.4 8.615.56.9 1.7       Saito J*Jpn J Obstet Gynecol Pract* (2001)JapanExfol. cellsL1C1/L1C2380/0/0/38100.034.218.40.07.97.913.234.20.015.80.013.22.60.02.6 Sasagawa T*Cancer Epidemiol Biomarkers Prev* (2001)JapanExfol. cellsLCR-E71370/0/0/13791.235.82.22.29.52.213.110.92.90.05.87.30.00.00.7 Yoshikawa H*Jpn J Cancer Res* (1991)JapanBiopsiesL1C1/L1C2310/0/20/1190.338.79.7 6.512.93.212.9        Oh YL*Cytopathology* (2001)KoreaExfol. cellspU-1M/pU-2R420/0/0/4273.840.57.1 7.119.0          Lai HC*Int J Cancer* (2003)TaiwanExfol. cellsMY09/111410/0/0/14163.825.51.4  4.39.911.3        Ekalaksananan T*J Obstet Gynaecol. Res* (2001)ThailandExfol. cellsE1 primers4010/4/26/065.07.515.0  2.5          Lertworapreecha M*Southeast Asian J Trop. Med Public Health* (1998)ThailandFixed biopsiesMY09/11500/50/0/074.036.012.0  8.0          Limbaiboon T*Southeast Asian J Trop. Med Public Health* (2000)ThailandFixed biopsiesMY09/11210/21/0/0100.033.314.3  4.8                               *Asia sub-total*    72662/243/52/36976.431.46.91.04.96.710.511.21.62.33.04.00.40.50.7                                            *Europe*                      Baay MFD*Eur J Gynaecol. Oncol* (2001)BelgiumFixed biopsiesGP5+/6+9742/55/0/082.556.76.20.00.06.26.22.12.10.02.11.01.00.01.0 Tachezy R*Hum. Genet.* (1999)Czech RepublicExfol. cellsMY09/11880/0/0/8858.043.25.73.41.16.80.01.10.00.00.01.10.01.10.0 Sebbelov*Res Virol.* (1994)DenmarkFixed biopsiesGP5/6340/34/0/091.285.30.0 0.029.4          Bergeron B*Am J Surg Pathol* (1992)FranceFresh biopsiesL1 primers530/0/0/5392.556.63.8  1.9          Merkelbach-Bruse S*Diagn Mol. Pathol* (1999)GermanyFixed biopsiesGP5/68821/67/0/078.461.41.1 3.41.1          Meyer T*Int J Gynecol Cancer* (2001)GermanyFresh biopsiesMY09/112880/0/0/28894.446.26.61.413.29.41.75.63.10.71.41.00.31.42.1 Nindl I*J Clin Pathol* (1999)GermanyExfol. cellsGP5+/6+6531/34/0/087.756.96.21.518.57.70.00.00.00.00.00.00.00.01.5 Nindl I*Int J Gynecol Pathol* (1997)GermanyExfol. CellsGP5+/6+850/0/0/8583.536.52.4 5.912.9          Labropoulou V*Sex Transm Dis* (1997)GreeceFresh biopsiesMY09/11500/0/0/5088.036.012.0 6.06.0     4.0  0.0 Paraskevaidis E*Gynecol Oncol* (2001)GreeceExfol. cellsMY09/11280/0/0/2889.335.77.13.625.014.30.00.00.0 0.00.0 0.0  Sebbelov*Res Virol*. (1994)GreenlandFixed biopsiesGP5/6300/30/0/063.370.03.3 6.710.0          Butler D*J Pathol* (2000)IrelandFixed biopsiesTS-PCR only270/27/0/085.270.43.7 3.73.70.00.0        O\'Leary JJ*Hum. Pathol* (1998)IrelandFixed biopsiesGP5/6200/20/0/095.095.00.0  0.0          Laconi*Pathologica* (2000)ItalyFixed biopsiesGP5+/6+3619/17/0/0100.050.08.3 2.8  2.85.6 5.62.80.00.0  Zerbini M*J Clin Pathol* (2001)ItalyExfol. cellsMY09/11890/0/0/8979.850.63.42.27.99.0          Medeiros R*Proceedings of International Meeting of Gynaecological Oncology* (1997)PortugalFixed biopsiesMY09/117810/68/0/085.982.10.0  1.3          Bosch*Cancer Epidemiol Biomarkers Prev* (1993)SpainExfol. cellsMY09/111570/157/0/070.749.00.6 1.35.7  0.6       Kalantari M*Hum. Pathol* (1997)SwedenExfol. cellsMY09/1116469/95/0/082.936.07.3 7.310.4          Zehbe I*Virchows Arch* (1996)SwedenFixed biopsiesGP5+/6+10355/48/0/095.150.59.71.97.89.71.90.07.8 1.90.0    Bollen LJM*Am J Obstet Gynecol* (1997)The NetherlandsExfol. cellsCpI/CPIIG9124/64/0/397.836.34.44.418.75.57.72.24.4 1.14.43.3   Cornelissen MTE*Virchows Arch B Cell Pathol Incl. Mol. Pathol* (1992)The NetherlandsFixed biopsiesMY09/118916/73/0/088.852.86.7 12.45.6          Reesink-Peters N*Eur J Obstet Gynecol Reprod Biol* (2001)The NetherlandsExfol. cellsSPF1021644/172/0/097.756.913.9 19.411.6    8.3     Arends MJ*Hum. Pathol* (1993)UKFixed biopsiesTS-PCR only4020/20/0/060.050.010.0  0.0          Cuzick J*Br J Cancer* (1994)UKExfol. cellsTS-PCR only7312/61/0/091.863.020.5 26.016.4  2.7       Giannoudis A*Int J Cancer* (1999)UKFixed biopsiesGP5+/6+11831/87/0/0100.068.64.20.014.411.03.40.82.50.00.02.50.00.82.5 Herrington CS*Br J Cancer* (1995)UKExfol. cellsMY09/113812/26/0/092.150.07.9 18.47.9          Southern SA*Diagn Mol. Pathol* (1998)UKFixed biopsiesGP5+/6+260/26/0/0100.061.57.70.015.43.80.00.00.00.00.00.00.00.03.8                      *Europe sub-total*    2271406/1181/0/68487.152.66.51.710.58.42.62.42.60.32.51.50.60.81.6                      *North America*                      Sellors JW*Can Med Assoc J*. (2000)CanadaExfol. cellsMY09/11580/0/0/5898.375.98.60.027.65.20.00.00.00.00.00.00.00.00.0 Adam E*Am J Obstet Gynecol* (1998)USAExfol. cellsMY09/112570/0/0/25778.251.013.6 1.94.7  13.6       Aoyama C*Diagn Mol. Pathol* (1998)USAFixed biopsiesMY09/11214/15/0/295.252.40.0 19.019.0          Schiff M*Am J Epidemiol* (2000)USAExfol. cellsMY09/1111270/42/0/077.717.04.51.822.34.516.14.54.54.512.54.52.76.39.8                      *North America sub-total*    44874/57/0/31781.545.810.01.211.25.410.62.99.42.98.22.91.84.16.5                      *South/Central America*                      Abba MC*International Papillomavirus Conference Proceedings* (2001)ArgentinaFixed biopsiesMY09/118613/24/0/4997.750.014.0 7.02.3     7.0    Alonio LV*Medicina (B Aires)* (2000)ArgentinaBiopsiesGP5+/6+360/36/0/080.641.711.1 0.05.6          Lorenzato F*Int J Gynecol Cancer* (2000)BrazilExfol. cellsMY09/11600/0/0/6086.756.73.33.33.38.310.00.01.7       Bosch*Cancer Epidemiol Biomarkers Prev* (1993)ColombiaExfol. cellsMY09/111250/125/0/063.232.80.0 2.42.4  1.6       Herrero R*J Natl Cancer Inst* (2000)Costa RicaExfol. cellsMY09/111250/0/0/12588.844.85.62.46.43.29.67.23.20.83.27.20.83.20.0 Ferrera A*Int J Cancer* (1999)HondurasExfol. cellsMY09/118336/47/0/080.734.97.23.68.44.87.21.21.20.01.20.00.00.00.0 Rattray*J Infect. Dis* (1996)JamaicaExfol. cellsMY09/116627/39/0/080.324.24.513.69.17.6  13.6       Strickler HD*J Med Virol.* (1999)JamaicaExfol. cellsMY09/11183111/72/0/092.323.510.94.48.77.712.69.311.55.52.24.92.21.14.9 Illades-Aguiar*International Papillomavirus Conference Proceedings* (2001)MexicoFresh biopsiesMY09/11270/0/0/2785.237.03.70.014.814.83.70.00.00.00.00.00.00.00.0 Torroella-Kouri M*Gynecol Oncol* (1998)MexicoExfol. cellsMY09/11240/0/0/2483.358.312.50.00.08.312.50.00.00.00.04.20.00.00.0                      *South/Central America sub-total*    815187/343/0/28584.336.97.14.46.45.510.25.45.52.52.04.71.11.42.0                      Total    4338729/1824/52/173384.245.07.12.38.87.26.95.24.41.53.02.91.01.12.1[^6]

[^1]: HPV=human papillomavirus; SCC=squamous cell/unspecified carcinoma of the cervix; HSIL=high-grade squamous intraepithelial lesion; PCR=polymerase chain reaction;

[^2]: 'Broad'-spectrum PCR primers include MY09/11, GP5+/6+ and SPF10.

[^3]: 'Narrow'-spectrum PCR primers include GP5/6, L1C1/C2 and PU1M/2R.

[^4]: HPV=human papillomavirus; SCC=squamous cell/unspecified carcinoma of the cervix; HSIL=high-grade squamous intraepithelial lesion.

[^5]: With 95% confidence intervals.

[^6]: Exfol. Cells=exfoliated cells.
